Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formycin is a naturally occurring pyrazole-containing C-nucleoside antibiotic, primarily known through its active form, Formycin A. It functions as an adenosine analog and interferes with nucleic acid metabolism. Formycin A exhibits a range of biological activities including antibacterial, antiviral, and antitumor properties. Its mechanisms involve acting as a substrate analog for RNA polymerases, leading to its incorporation into RNA, and inhibiting key enzymes in the purine salvage pathway such as purine nucleoside phosphorylase and adenylosuccinate synthetase. In cancer, Formycin A has been shown to induce cell death by upregulating death receptor 5 and activating the extrinsic apoptosis pathway through the induction of endoplasmic reticulum stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Formycin.